UNCY - Unicycive Therapeutics to be Featured in Multiple Presentations at the Upcoming European Renal Association Congress | Benzinga
LOS ALTOS, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (NASDAQ:UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the "Company or "Unicycive"), today announced that multiple presentations will be delivered on the Company's product candidates, oxylanthanum carbonate (OLC) and UNI-494, at the 61st European Renal Association (ERA) Congress taking place May 23-26, 2024, in Stockholm, Sweden.
Shalabh Gupta, MD, Chief Executive Officer of Unicycive, commented, "The ERA Congress is one of the most prominent nephrology meetings of the year, and we are excited to deliver presentations on both OLC and UNI-494. In addition to presenting preclinical data supporting both of our programs, we will also be reporting on our two clinical trials in progress. We look forward to participating in this important event."
Oxylanthanum Carbonate (OLC)
| Title: |
| Enhanced Urinary Phosphorous Reduction: Comparative Study of Oxylanthanum Carbonate and Tenapanor in Rats |
| Lead Author: |
| Satya Medicherla, Ph.D., Vice President, Preclinical Pharmacology, Unicycive |
| Type: |
| Focused Oral Presentation |
| Dates/Times: |
| May 25, 2024 from 12:10 p.m. – 12:15 p.m. CEST |
| Title: |
| Oxylanthanum Carbonate for Hyperphosphatemia in End Stage Kidney Disease (ESKD): Tolerability Trial in Progress |
| Lead Author: |
| Pablo E. Pergola, M.D., Ph.D., Renal Associates, P.A. |
| Type: |
| ePoster |
| Date/Time: |
| Available throughout the conference |
UNI-494
| Title: |
| Oral Administration of UNI-494 Ameliorates Acute Kidney Injury in a Rat Model of Delayed Graft Function |
| Lead Author: |
| Satya Medicherla, Ph.D., Vice President, Preclinical Pharmacology, Unicycive |
| Type: |
| Focused Oral Presentation |
| Dates/Times: |
| May 25, 2024 from 12:00 p.m. – 12:05 p.m. CEST |
| Title: |
| UNI-494 Phase I Tolerability and Pharmacokinetics: Trial in Progress |
| Lead Author: |
| Guru Reddy, Ph.D., Vice President of Preclinical R&D, Unicycive |
| Type: |
| Focused Oral Presentation |
| Dates/Times: |
| May 25, 2024 from 12:45 p.m. – 12:50 p.m. CEST |
About Oxylanthanum Carbonate (OLC)
Oxylanthanum carbonate is a next-generation lanthanum-based phosphate binding agent utilizing proprietary nanoparticle technology being developed for the treatment of hyperphosphatemia in patients with chronic kidney disease (CKD). OLC has over forty issued and granted patents globally. Its potential best-in-class profile may have meaningful patient adherence benefits over currently available treatment options as it requires a lower pill burden for patients in terms of number and size of pills per dose that are swallowed instead of chewed. Based on a survey conducted in 2022, Nephrologists stated that the greatest unmet need in the treatment of hyperphosphatemia with phosphate binders is a lower pill burden and better patient compliance.1 The global market opportunity for treating hyperphosphatemia is projected to be in excess of $2.5 billion in 2023, with the United States accounting for more than $1 billion of that total. Despite the availability of several FDA-cleared ...